본문으로 건너뛰기
← 뒤로

Analysis of risk factors for infusion-related reactions in patients with B-cell lymphoma during obinutuzumab treatment.

1/5 보강
Journal of chemotherapy (Florence, Italy) 📖 저널 OA 2.1% 2023: 0/1 OA 2024: 0/1 OA 2025: 1/18 OA 2026: 0/27 OA 2023~2026 2026 p. 1-10
Retraction 확인
출처

PICO 자동 추출 (휴리스틱, conf 3/4)

유사 논문
P · Population 대상 환자/모집단
100 patients (48 men, 52 women) with a mean age of 55.
I · Intervention 중재 / 시술
obinutuzumab
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
Multivariate analysis identified splenomegaly and pre-treatment LDH levels as IRR risk factors. This research assists in predicting IRRs to improve patient outcomes.

Wang Z, Zhang Y, Zhao D, Wei C, Wang W, Zhou D

📝 환자 설명용 한 줄

This study investigated the risk factors associated with infusion-related reactions (IRRs) in B-cell lymphoma patients receiving obinutuzumab.

🔬 핵심 임상 통계 (초록에서 자동 추출 — 원문 검증 권장)
  • p-value P < 0.05

이 논문을 인용하기

↓ .bib ↓ .ris
APA Wang Z, Zhang Y, et al. (2026). Analysis of risk factors for infusion-related reactions in patients with B-cell lymphoma during obinutuzumab treatment.. Journal of chemotherapy (Florence, Italy), 1-10. https://doi.org/10.1080/1120009X.2026.2640329
MLA Wang Z, et al.. "Analysis of risk factors for infusion-related reactions in patients with B-cell lymphoma during obinutuzumab treatment.." Journal of chemotherapy (Florence, Italy), 2026, pp. 1-10.
PMID 41804192 ↗

Abstract

This study investigated the risk factors associated with infusion-related reactions (IRRs) in B-cell lymphoma patients receiving obinutuzumab. A retrospective analysis of Peking Union Medical College Hospital patients (January 2021-December 2024) was conducted to examine factors between patients experiencing IRRs ( = 44) and those without ( = 56). Parameters included gender, age, histological subtype, treatment status, Ann Arbor staging, extranodal/bone marrow involvement, bulky disease, splenomegaly status, serum lactate dehydrogenase (LDH), beta-2 microglobulin (βMG) concentrations, and lymphocyte count. 100 patients (48 men, 52 women) with a mean age of 55.7 years (range: 44-67) received obinutuzumab. Univariate analyses showed higher prevalence of bone marrow involvement and splenomegaly in the IRR group. Median LDH (235 195) and βMG (4 vs. 3) levels pre-treatment were significantly elevated in the IRR group (P < 0.05). Multivariate analysis identified splenomegaly and pre-treatment LDH levels as IRR risk factors. This research assists in predicting IRRs to improve patient outcomes.

🏷️ 키워드 / MeSH 📖 같은 키워드 OA만

같은 제1저자의 인용 많은 논문 (5)

🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반